Study design. (A) All patients in the control arm received rabbit ATG (Genzyme, a Sanofi company) at the same dose of 2.5 mg/kg for 4 consecutive days. Inolimomab was delivered IV at a dose of 0.3 mg/kg per day for the induction phase and 0.2 mg/kg per day for maintenance. (B) Study design for the inolimomab arm.